Clinical Study of JS201 in Patients With Advanced Malignant Tumors

Summary

This is an open label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary efficacy of JS201 in the patients with advanced malignant tumors who have progression after or during the standard of care, or no effective standard therapeutic regimen. This study is divided into three phases: dose-escalation phase, dose expansion phase, and clinical expansion phase.

Timeline

Start

2021-07-29

Primary completion

2023-07-07

Completion

2023-07-07

Drugs

Indications